...
首页> 外文期刊>Cancer letters >Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation.
【24h】

Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation.

机译:隐丹参酮通过Bcl-2和MAPK调节使DU145前列腺癌细胞对Fas(APO1 / CD95)介导的凋亡敏感。

获取原文
获取原文并翻译 | 示例
           

摘要

Fas/APO-1/CD95, a member of the tumor necrosis factor (TNF) receptor superfamily, is a potential anti-cancer factor as it can induce apoptosis in tumor cells. However, despite the fact that many cancer cells express Fas on the membrane, some tumors such as prostate cancer display resistance to Fas-induced apoptosis. In these cases, combination therapy using chemotherapeutic agents and Fas may be more suitable than therapy using Fas alone. In the present study, we demonstrate that the apoptosis inhibitory protein, Bcl-2, was highly expressed in response to Fas in DU145 prostate cancer cells, thereby conferring resistance to apoptosis. We have screened a number of naturally occurring products that may overcome this resistance. Here we report that cryptotanshinone, the major tanshinone isolated from Salvia miltiorrhiza Bunge, can suppress Bcl-2 expression and augment Fas sensitivity in DU145 cells. We further show that JNK and p38 MAPK act upstream of Bcl-2 expression in Fas-treated DU145 cells, and that cryptotanshinone significantly blocked activation of these kinases. Moreover, cryptotanshinone sensitized several tumor cells to a broad range of anti-cancer agents. Collectively, our data suggest that cryptotanshinone has therapeutic potential in the treatment of human prostate cancer.
机译:Fas / APO-1 / CD95是肿瘤坏死因子(TNF)受体超家族的成员,是一种潜在的抗癌因子,因为它可以诱导肿瘤细胞凋亡。然而,尽管事实上许多癌细胞在膜上表达Fas,但某些肿瘤(例如前列腺癌)仍表现出对Fas诱导的细胞凋亡的抵抗力。在这些情况下,使用化学治疗剂和Fas的联合治疗可能比单独使用Fas的治疗更合适。在本研究中,我们证明了凋亡抑制蛋白Bcl-2在DU145前列腺癌细胞中高表达Fas,从而赋予了对凋亡的抗性。我们筛选了许多可以克服这种抗性的天然产物。在这里我们报告隐丹参酮,从丹参丹参中分离出的主要丹参酮,可以抑制Bcl-2表达并增加DU145细胞中的Fas敏感性。我们进一步表明,JNK和p38 MAPK在Fas处理的DU145细胞中Bcl-2表达的上游起作用,并且隐丹参酮显着阻断了这些激酶的激活。此外,隐丹参酮使几种肿瘤细胞对多种抗癌药敏感。总体而言,我们的数据表明隐丹参酮在治疗人类前列腺癌方面具有治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号